Halozyme Therapeutics, Inc. (HALO)
109.86
+2.92
(+2.73%)
USD |
NASDAQ |
Oct 02, 16:00
109.79
-0.07
(-0.06%)
After-Hours: 20:00
Halozyme Therapeutics Enterprise Value : 14.44B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 14.44B |
| October 01, 2026 | 14.11B |
| September 30, 2026 | 14.51B |
| September 29, 2026 | 14.64B |
| September 28, 2026 | 14.79B |
| September 25, 2026 | 14.91B |
| September 24, 2026 | 15.06B |
| September 23, 2026 | 14.74B |
| September 22, 2026 | 15.05B |
| September 21, 2026 | 14.63B |
| September 18, 2026 | 14.74B |
| September 17, 2026 | 14.42B |
| September 16, 2026 | 14.28B |
| September 15, 2026 | 14.03B |
| September 14, 2026 | 14.23B |
| September 11, 2026 | 14.14B |
| September 10, 2026 | 14.12B |
| September 09, 2026 | 14.16B |
| September 08, 2026 | 14.27B |
| September 04, 2026 | 14.48B |
| September 03, 2026 | 14.55B |
| September 02, 2026 | 14.42B |
| September 01, 2026 | 14.20B |
| August 31, 2026 | 14.06B |
| August 28, 2026 | 13.93B |
| Date | Value |
|---|---|
| August 27, 2026 | 14.11B |
| August 26, 2026 | 14.12B |
| August 25, 2026 | 14.38B |
| August 24, 2026 | 14.31B |
| August 21, 2026 | 14.25B |
| August 20, 2026 | 14.02B |
| August 19, 2026 | 14.19B |
| August 18, 2026 | 13.88B |
| August 17, 2026 | 13.66B |
| August 14, 2026 | 13.17B |
| August 13, 2026 | 13.40B |
| August 12, 2026 | 13.52B |
| August 11, 2026 | 13.62B |
| August 10, 2026 | 13.62B |
| August 07, 2026 | 13.68B |
| August 06, 2026 | 11.70B |
| August 05, 2026 | 11.45B |
| August 04, 2026 | 11.41B |
| August 03, 2026 | 11.30B |
| July 31, 2026 | 11.33B |
| July 30, 2026 | 11.42B |
| July 29, 2026 | 11.41B |
| July 28, 2026 | 11.43B |
| July 27, 2026 | 11.21B |
| July 24, 2026 | 11.26B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AVITA Medical, Inc. | 430.73M |
| Iovance Biotherapeutics, Inc. | 6.187B |
| Incyte Corp. | 18.68B |
| BioCryst Pharmaceuticals, Inc. | 2.569B |
| Neurocrine Biosciences, Inc. | 14.56B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 229.91M |
| Revenue (Quarterly) | 481.00M |
| Total Expenses (Quarterly) | 251.09M |
| EPS Diluted (Quarterly) | 1.897 |
| Gross Profit Margin (Quarterly) | 77.40% |
| Profit Margin (Quarterly) | 47.80% |
| Earnings Yield | 3.05% |
| Operating Earnings Yield | 7.10% |
| Normalized Earnings Yield | 4.957 |